Search Articles

View query in Help articles search
e.g. mhealth

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS

Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study

Preparing for the Implementation of Long-Acting Injectable Cabotegravir for HIV Pre-Exposure Prophylaxis Within the Brazilian Public Health System (ImPrEP CAB Brasil): Qualitative Study

Long-acting, injectable cabotegravir (CAB-LA) has proven efficacious for HIV prevention in phase 3 clinical trials (HIV Prevention Trials Network [HPTN] 083 and HPTN 084) [16,17]. Data from these studies led to the recommendation of CAB-LA for HIV prevention by the World Health Organization in July 2022 [18]. In Brazil, CAB-LA for HIV prevention has regulatory approval, but this strategy is not yet incorporated in the Brazilian Pr EP Guidelines and is not available through the public health system.

M Cristina Pimenta, Thiago Silva Torres, Brenda Hoagland, Mirian Cohen, Claudio Gruber Mann, Cristina M Jalil, Eduardo Carvalheira, Lucilene Freitas, Nilo Fernandes, Debora Castanheira, Marcos Benedetti, Julio Moreira, Keila Simpson, Roberta Trefiglio, Gabrielle O’Malley, Valdilea G Veloso, Beatriz Grinsztejn

JMIR Public Health Surveill 2024;10:e60961

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 1

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study

Long-acting injectable cabotegravir (CAB-LA) is an integrase strand-transfer inhibitor, and its effectiveness for Pr EP has been demonstrated in phase 2b/3 studies (HIV Prevention Trials Network [HPTN] 083 and HPTN 084) [25,26]. HPTN 083 was a double-blind double-dummy randomized controlled trial that assessed the effectiveness of CAB-LA for Pr EP compared with oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) Pr EP among 4566 cisgender MSM and TGW under high susceptibility to HIV.

Beatriz Grinsztejn, Thiago Silva Torres, Brenda Hoagland, Emilia Moreira Jalil, Ronaldo Ismerio Moreira, Gabrielle O'Malley, Starley B Shade, Marcos R Benedetti, Julio Moreira, Keila Simpson, Maria Cristina Pimenta, Valdiléa Gonçalves Veloso, The ImPrEP CAB-Brasil Study Team

JMIR Public Health Surveill 2023;9:e44961

Download Citation: END BibTex RIS

Download PDF Download XML
Article has an altmetric score of 18